Skip to Main Content

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning, everyone. Damian here with a look at the legacy of a pharma CEO, yet more biotech layoffs, and a reprieve from the GLP-1 panic.

advertisement

How will we remember Humira?

For the last decade, AbbVie CEO Richard Gonzalez has presided over the drug industry’s most enviable cash cow, making billions in sales on the autoimmune treatment Humira despite the expiration of the drug’s core patents. With Gonzalez now slated to step down, what will the industry remember: the lucrative returns or the unceasing controversy?

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.